FX 1006A,
FX-1006A,
FX1006A,
tafamidis,
tafamidis meglumine,
Vyndamax,
Vyndaqel,
TAFAMIDIS,
594839-88-0,
2-(3,5-Dichlorophenyl)-1,3-Benzoxazole-6-Carboxylic Acid,
FX-1006,
2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid,
UNII-8FG9H9D31J,
CHEBI:78538,
8FG9H9D31J,
2-(3,5-Dichlorophenyl)-6-benzoxazolecarboxylic Acid,
C14H7Cl2NO3,
2-(3,5-dichlorophenyl)benzoxazole-6-carboxylic acid,
Tafamidis [USAN:INN],
tafamidisum,
4his,
Fx 1006,
3MI,
Tafamidis (USAN/INN),
SCHEMBL442508,
GTPL8378,
CHEMBL2103837,
KS-00000TIG,
DTXSID00208185,
BCP29089,
3096AH,
BDBM50197883,
MFCD16621109,
ZINC43206271,
AKOS017550076,
CS-2821,
DB11644,
VS-0125,
AK222900,
AN-27718,
HY-14852,
DB-072645,
FT-0674793,
A14111,
D09673,
839D880,
2-(3,5-Dichloro-phenyl)-benzooxazole-6-carboxylic acid,
6-Benzoxazolecarboxylic acid, 2-(3,5-dichlorophenyl)-,
Z2588039578,
Discontinued until Pfizer approves it for our agreement"",
FX-1006A|||2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid,
Vyndaqel,
Tafamidis meglumine,
Vyndaqel (TN),
Tafamidis [USAN],
D04DFR,
14H7Cl2NO3,
Fx-1006A,
Fx1006A,
Fx 1006A,
FX005,
FX 005,
ACN-036888,
CID11001318,
PF-06291826,
2-(3,5-dichlorophenyl)benzooxazole-6-carboxylic Acid,
137464-18-7,